CharlesDayritLopezMD

Oncology • Portland, OR

Associate Professor, Medicine, Oregon Health and Science University School of Medicine

Join to view full profile

Dr. Lopez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lopez's full profile

Already have an account?

Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239
Phone+1 503-494-6594

Fax+1 503-494-3257

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1995 - 1998
University of California (San Francisco)Residency, Internal Medicine, 1991 - 1994
University of California San Francisco School of MedicineClass of 1991

Certifications & Licensure

CA State Medical License 1992 - Present
OR State Medical License 2001 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 1
Targeted Pathway Inhibition in Patients With Pancreatic Cancer Start of enrollment: 2019 Aug 01
Recruiting
Early Phase 1
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer Start of enrollment: 2021 May 27
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2022 Aug 09
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Start of enrollment: 2024 Jun 01
Not yet recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2 citations
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: ...
Philip A Philip, Vaibhav Sahai, Nathan Bahary, Amit Mahipal, Anup Kasi
Journal of Clinical Oncology. 2024-11-01
Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer.
Ranish K Patel, Michael Parappilly, Hannah C Farley, Emile J Latour, Lei G Wang
Cancers. 2024-10-29
ASO Author Reflections: Is It Time to Re-evaluate Floxuridine Dosing for Hepatic Arterial Infusion?
Issac R Schwantes, Ranish K Patel, Adel Kardosh, Charles D Lopez, Skye C Mayo
Annals of Surgical Oncology. 2024-10-01

Journal Articles

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma
Brett Sheppard, Charles D Lopez, Zipei Feng, Clinical Cancer Research

Press Mentions

Peptomyc Announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC PatientsSeptember 12th, 2024

Grant Support

Mechanisms Linking ASPP2 To The RB/E2F And P53 PathwaysNational Cancer Institute2004–2008
P53 And UV Regulation Of P53 Binding Protein Bbp/53bp2National Cancer Institute2001–2004
P53 And UV Regulation Of P53 Binding Protein Bbp/53bp2National Cancer Institute2000–2001

Professional Memberships

American Society of Clinical Oncology - ASCO
Member